INGELHEIM, Germany I, 2025 I Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC)∗ and OXB,ŧ today announce the start ...

Scotland draws in researchers, students and innovators from around the world. It's a thriving and lively country: one that ...

Their unparalleled opportunities for attaining a degree with worldwide recognition include being based in an incredibly ...

This year the competition, co-founded by Cyrus and Pervin Todiwala with the support of the Master Chefs of Great Britain, will be contested by Edinburgh College, Loughborough College, Milton Keynes ...

Ukrainians who have settled in Stirling since the Russian invasion of their homeland three years ago have reflected on life ...

An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis is being tested in human ...

An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their mutation type, is being tested in human trials in the UK and Europe.

Boehringer Ingelheim, IP Group, UK Respiratory Gene Therapy Consortium, and OXB launched the first-in-human clinical trial, known as LENTICLAIR 1.

A £9m virtual production studio has opened in Dundee, with the goal of promoting research, innovation and economic growth ...

Researchers at Imperial College London are leading human trials for the innovative treatmentAn inhalable medicine with the potential to improve lung ...

An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their mutation type, is being tested in human trials in the UK and Europe.